For instance, we identified nine cases of BRAF/MEK inhibitor (dabrafenib + trametinib) ineligibility due to a diagnosis change to colorectal adenocarcinoma (Supplementary Fig. S9; ref. 53). Here, BRAF is linked to colorectal adenocarcinoma.